Agilent Technologies Inc. (NYSE: A) has introduced its first comparative genomic hybridization (CGH) assay for diagnostic use: the GenetiSure Dx Postnatal Assay. This assay will enable clinical geneticists to detect genetic anomalies earlier and more accurately than traditional methods can.
Such anomalies have been associated with developmental delay, intellectual disability, autism, congenital irregularities and dysmorphic features in children and adults.
The GenetiSure Dx Postnatal
RelSci News & Alerts gets you: